Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Sohail Rahmany
Observed name:
S Rahmany
Institution:
University Hospital Southampton NHS Foundation Trust
Observed institutions:
Southampton General Hospital,
Royal Hampshire County Hospital,
University Hospital Southampton NHS Foundation Trust,
Hampshire Hospitals NHS Foundation Trust,
University of Southampton
ORCID:
0000-0003-0924-2690
Observed ORCID:
0000-0003-0924-2690
OpenAlex ID:
A5083327434
Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab
2022
·
Simeng Lin
, Nicholas A. Kennedy
, et al.
·
Nature Communications
·
108
PDF
Transitioning from Intravenous to Subcutaneous Vedolizumab in Patients with Inflammatory Bowel Disease [TRAVELESS]
2021
·
Esther Ventress
, David Young
, et al.
·
Journal of Crohn s and Colitis
·
59
PDF
Assessment, endoscopy, and treatment in patients with acute severe ulcerative colitis during the COVID-19 pandemic (PROTECT-ASUC): a multicentre, observational, case-control study
2021
·
Shaji Sebastian
, Gareth J Walker
, et al.
·
The Lancet. Gastroenterology & hepatology
·
41
PDF
Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort study
2022
·
Zhigang Liu
, Kaixing Le
, et al.
·
The Lancet. Gastroenterology & hepatology
·
39
Real-world assessment of effectiveness and safety of filgotinib in 286 patients with ulcerative colitis in 9 UK centres
2025
·
David Young
, Sohail Rahmany
, et al.
·
Drugs in Context
·
14
PDF
Effectiveness of Switching From Intravenous to Subcutaneous Infliximab in Patients With Inflammatory Bowel Disease: An individual participant data meta-analysis
2025
·
Fraser Cummings
, Philip J. Smith
, et al.
·
Journal of Clinical Gastroenterology
·
6
PTH-157 The Introduction of Biosimilar Infliximab (CT-P13) through A Managed Switching Programme Generates Significant Cost Savings with High Levels of Patient Satisfaction
2016
·
S Rahmany
, S Cotton
, et al.
·
Gut
·
6
Impact of direct-access IBD physician delivered endoscopy on clinical outcomes: a pre-implementation and post-implementation study
2022
·
Matthew Stammers
, Sohail Rahmany
, et al.
·
Frontline Gastroenterology
·
5
PDF
PTU-073 In Patients with IBD Switching from Originator Infliximab (Remicade) to Biosimilar Infliximab (CT-P13) Is Safe and Effective
2016
·
S Rahmany
, S Cotton
, et al.
·
Gut
·
5
A randomised, crossover trial exploring the patient perspective and effectiveness of biosimilar adalimumab transition: IBD reference and biosimilar adalimumab cross over study (iBaSS)
2024
·
David Young
, Clare Harris
, et al.
·
International Journal of Clinical Pharmacy
·
3
P389 Switching infliximab to subcutaneous from intravenous therapy (SWIMSUIT) – A prospective, real-world, single centre, phase IV interventional study.
2023
·
S Rahmany
, D Young
, et al.
·
Journal of Crohn s and Colitis
·
3
P333 Impact of IBD remote monitoring introducing a patient-initiated follow-up (PIFU) model
2025
·
Kit Morris
, Eleanor Gudgeon
, et al.
·
Gut
·
2
P114 Filgotinib in ulcerative colitis: early real-world experience in Southampton
2023
·
Deborah Taylor
, David Young
, et al.
·
Gut
·
2
PMO-15 Transitioning from intravenous to subcutaneous vedolizumab in patients with inflammatory bowel disease (TRAVELESS)
2021
·
Esther Ventress
, Sohail Rahmany
, et al.
·
Gut
·
2
PDF
P323 Calprotectin home testing with digital integration into the electronic health record (EHR) in an inflammatory bowel disease (IBD) support service
2025
·
Markus Gwiggner
, Evangeline Ganeshamoorthy
, et al.
·
Gut
·
1
P712 Effectiveness of switching from intravenous to subcutaneous infliximab in Inflammatory Bowel Disease patients: A combined analysis of real-world evidence
2024
·
F Cummings
, A Buisson
, et al.
·
Journal of Crohn s and Colitis
·
1
PDF
P96 Patient benefits of switching from intravenous to subcutaneous infliximab
2023
·
Sohail Rahmany
, David Young
, et al.
·
Gut
·
1
P1092 Are Inflammatory Bowel Disease MDT Meeting Patients Known To The Dietitians?
2026
·
V Katarachia
, C Westoby
, et al.
·
Journal of Crohn s and Colitis
FP42 Digital transformation of an IBD support service using the digital platform MyMR/NETCALL
2025
·
Eleanor Gudgeon
, Kit Morris
, et al.
·
Gut
P48 Comparison of referral-to-treatment times for inflammatory bowel disease: gastroenterologist vs non-gastroenterologist in the colorectal cancer pathway
2025
·
Sohail Rahmany
, Frederick Dowuona-Owoo
, et al.
·
Gut
Su1827 FILGOTINIB IN ULCERATIVE COLITIS: EARLY REAL-WORLD MULTICENTRE UK EXPERIENCE
2024
·
David Young
, Sohail Rahmany
, et al.
·
Gastroenterology
Mo1854 EFFECTIVENESS OF SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUS INFLIXIMAB IN INFLAMMATORY BOWEL DISEASE PATIENTS: A COMBINED ANALYSIS OF REAL-WORLD EVIDENCE
2024
·
Fraser Cummings
, Anthony Buisson
, et al.
·
Gastroenterology
Mo1869 SUBCUTANEOUS INFLIXIMAB EFFECTIVELY MANAGES CLINICAL OUTCOMES OF INFLAMMATORY BOWEL DISEASE INDEPENDENTLY OF VARIOUS CONFOUNDING FACTORS
2024
·
Anthony Buisson
, Fraser Cummings
, et al.
·
Gastroenterology
P1015 Subcutaneous infliximab effectively manages clinical outcomes of Inflammatory Bowel Disease independently of various confounding factors
2024
·
A Buisson
, F Cummings
, et al.
·
Journal of Crohn s and Colitis
PDF
P875 Filgotinib in ulcerative colitis: early real-world multicentre UK experience
2024
·
D Young
, S Rahmany
, et al.
·
Journal of Crohn s and Colitis
PDF
Show more works
View as search
Works count:
33
Citation count:
298
H-index:
6
I10-index:
5
Year
Topic
Type